drew a lot of media and industry attention. In this context, Leqembi, and in future possibly other beta amyloid-targeted monoclonal antibodies, is covered by Medicare provided patients enroll in a patient registry along with a few other conditions.
But CMS may have too much on its plate if it must do its everyday administrative, oversight and payment duties, in addition to HTA and drug price negotiations. As such, it would be shielded from some of the political pressure that CMS operates under. CMS is after all an agency which acts under the auspices of the executive branch of government.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: